TY - JOUR
T1 - Relapses after treatment with rituximab in a patient with multiple sclerosis and anti-myelin-associated glycoprotein polyneuropathy
AU - Benedetti, Luana
AU - Franciotta, Diego
AU - Vigo, Tiziana
AU - Grandis, Marina
AU - Fiorina, Elisabetta
AU - Ghiglione, Elisabetta
AU - Roccatagliata, Luca
AU - Mancardi, Giovanni Luigi
AU - Uccelli, Antonio
AU - Schenone, Angelo
PY - 2007/10
Y1 - 2007/10
N2 - Objective: To describe the unique case of a patient with multiple sclerosis (MS) and anti-myelin-associated glycoprotein (MAG) polyneuropathy who developed MS relapses after treatment with rituximab. Design: Case report. Setting: Department of Neurosciences, Ophthalmology, and Genetics, University of Genova, Genova, Italy. Patient: A 59-year-old man with an 18-year history of MSpresented with an unusually rapid progression of paraparesis with hypopallesthesia and areflexia in 4 limbs. Neurophysiological and serological studies led to the diagnosis of anti-MAG polyneuropathy. Cerebrospinal fluid analysis disclosed the loss of oligoclonal IgG bands that were previously detected at MS onset. Intervention: Rituximab was administered at a dosage of 375 mg/m2/wk for 4 weeks. Result: The patient developed 2 corticosteroid-responsive MS relapses with improvement of the polyneuropathy. Conclusion: Rituximab can be effective in anti-MAG polyneuropathy but can possibly lead to unexpected consequences in individuals with MS.
AB - Objective: To describe the unique case of a patient with multiple sclerosis (MS) and anti-myelin-associated glycoprotein (MAG) polyneuropathy who developed MS relapses after treatment with rituximab. Design: Case report. Setting: Department of Neurosciences, Ophthalmology, and Genetics, University of Genova, Genova, Italy. Patient: A 59-year-old man with an 18-year history of MSpresented with an unusually rapid progression of paraparesis with hypopallesthesia and areflexia in 4 limbs. Neurophysiological and serological studies led to the diagnosis of anti-MAG polyneuropathy. Cerebrospinal fluid analysis disclosed the loss of oligoclonal IgG bands that were previously detected at MS onset. Intervention: Rituximab was administered at a dosage of 375 mg/m2/wk for 4 weeks. Result: The patient developed 2 corticosteroid-responsive MS relapses with improvement of the polyneuropathy. Conclusion: Rituximab can be effective in anti-MAG polyneuropathy but can possibly lead to unexpected consequences in individuals with MS.
UR - http://www.scopus.com/inward/record.url?scp=35348819430&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=35348819430&partnerID=8YFLogxK
U2 - 10.1001/archneur.64.10.1531
DO - 10.1001/archneur.64.10.1531
M3 - Article
C2 - 17923639
AN - SCOPUS:35348819430
VL - 64
SP - 1531
EP - 1533
JO - Archives of Neurology
JF - Archives of Neurology
SN - 0003-9942
IS - 10
ER -